Alison Crawford, PhDSenior Staff Scientist, Oncology and Angiogenesis at Regeneron Pharmaceuticals
Dr. Alison Crawford is a Senior Staff Scientist in the department of Oncology and Angiogenesis at Regeneron Pharmaceuticals, Inc. She has >18 years of immunology research experience, including > 8 years in the pharmaceutical industry. She specializes in the pre-clinical development of bispecific antibodies for oncology indications. She completed her BSc in Immunology from Glasgow University before being admitted to the Wellcome Trust Ph.D. program at Edinburgh University where she focused on T cell memory. Her post-doctoral work at the University of Pennsylvania examined T cell exhaustion during chronic viral infection and the role of checkpoint inhibition in alleviating this exhaustion. At Regeneron Pharmaceuticals, she leads a team that develops pre-clinical models to examine bispecific antibodies targeting solid tumors. She led the in vivo pre-clinical research efforts on REGN4018 (MUC16xCD3) to advance the antibody through to IND submission.